Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced it will host a key opinion leader event on September 18, 2025, to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. The event will focus on safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives highlighting the compound's potential role in addressing cancer drug resistance.

The significance of this announcement lies in the critical need for new therapeutic approaches to combat drug resistance in advanced prostate cancer. ENV105 represents an innovative approach targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. According to the company's research, elevation of CD105 in response to standard therapy results in resistance and disease relapse, making this target particularly important for improving patient outcomes.

For investors and the medical community, this event provides crucial insights into the clinical progress of a promising oncology therapeutic. The Phase 2 trial for castrate-resistant prostate cancer addresses significant unmet medical needs in a patient population with limited treatment options. The combination therapy approach being studied could potentially restore the effectiveness of standard therapies across multiple cancer types, representing a broader impact beyond prostate cancer treatment.

The company maintains its newsroom at https://ibn.fm/KAPA where stakeholders can access the latest updates and developments. This event's outcomes could influence both clinical practice and investment decisions in the oncology therapeutics space, particularly given the growing focus on combination therapies and mechanisms to overcome treatment resistance in cancer care.